阅读说明：本技术 一种隐孔菌子实体多糖及用于抑制黄嘌呤氧化酶活性治疗痛风的用途 (Cryptoporus volvatus fruiting body polysaccharide and application thereof in inhibiting xanthine oxidase activity to treat gout ) 是由 不公告发明人 于 2019-11-04 设计创作，主要内容包括：本发明公开了一种隐孔菌子实体多糖及用于抑制黄嘌呤氧化酶活性治疗痛风的用途。本发明发现,隐孔菌子实体多糖对黄嘌呤氧化酶具有较强的抑制活性。本领域技术人员知道,高尿酸血症和痛风均是体液中尿酸过高所导致,尿酸主要分为外源性和内源性,外源性尿酸主要通过食物摄入,内源性尿酸主要由XOD催化黄嘌呤及次黄嘌呤所产生,当体内XOD增高时会产生过多尿酸,尿酸浓度过高会导致高尿酸血症从而引发痛风。因此,隐孔菌子实体多糖具有开发成抗痛风药物的前景。(The invention discloses cryptoporus volvatus sporocarp polysaccharide and application thereof in inhibiting xanthine oxidase activity to treat gout. The invention discovers that the cryptoporus volvatus sporocarp polysaccharide has stronger inhibitory activity on xanthine oxidase. As known to those skilled in the art, hyperuricemia and gout are both caused by hyperuricemia in body fluid, uric acid is mainly divided into exogenous uric acid and endogenous uric acid, the exogenous uric acid is mainly taken in by food, the endogenous uric acid is mainly generated by catalyzing xanthine and hypoxanthine through XOD, hyperuricemia is generated when the XOD in a body is increased, and the hyperuricemia is caused by the excessive uric acid concentration, so that the gout is caused. Therefore, the cryptoporus volvatus fruiting body polysaccharide has a prospect of being developed into an anti-gout medicine.)

1. The cryptoporus volvatus fruiting body polysaccharide is characterized by being prepared by the following method: taking dried cryptoporus volvatus sporophore powder, heating and extracting with distilled water, filtering the extract, concentrating under reduced pressure, adding 3 times volume of anhydrous ethanol, standing overnight at 4 ℃, centrifuging, collecting precipitate, washing, redissolving with distilled water, deproteinizing by Sevag method, and freeze drying to obtain crude polysaccharide; taking the crude polysaccharide, redissolving the crude polysaccharide by using distilled water, loading the crude polysaccharide into a DEAE-Sepharose Fast Flow chromatographic column, eluting the crude polysaccharide by using distilled water and 1mol/L NaCl solution in sequence, collecting NaCl solution eluent, concentrating the eluent under reduced pressure, dialyzing, and freeze-drying to obtain the cryptoporus volvatus sporophore polysaccharide.

2. The cryptoporus volvatus fruit body polysaccharide according to claim 1, wherein: the precipitate obtained by water extraction and alcohol precipitation is washed by 75% ethanol, absolute ethanol and acetone in sequence.

3. The cryptoporus volvatus fruit body polysaccharide according to claim 1, wherein: when DEAE-Sepharose Fast Flow column was eluted, the elution volume of distilled water was 12 column volumes.

4. The cryptoporus volvatus fruit body polysaccharide according to claim 1, wherein: when DEAE-Sepharose Fast Flow column was eluted, the elution volume of 1mol/LNaCl solution was 10 column volumes.

5. Use of the polysaccharide of the fruit body of cryptoporus volvatus according to any one of claims 1 to 4 for inhibiting xanthine oxidase activity.

6. Use of the cryptoporus volvatus fruiting body polysaccharide of any one of claims 1 to 4 for the preparation of an anti-gout agent.

Technical Field

The invention belongs to the field of chemistry, and particularly relates to cryptoporus volvatus sporocarp polysaccharide and application of cryptoporus volvatus sporocarp polysaccharide in inhibiting xanthine oxidase activity to treat gout.

Background

Xanthine Oxidase (XOD) plays an important role in nucleic acid catabolism, can catalyze xanthine and hypoxanthine to produce uric acid, and simultaneously produce active oxygen and hydrogen peroxide in the metabolic process to cause oxidative stress, which are important factors for gout. Gout is a common inflammatory disease of joints, and is a metabolic inflammatory reaction disease caused by the existence of uric acid in the joints and cartilage tissues in the form of salt. Hyperuricemia and gout are both caused by overhigh uric acid in body fluid, the uric acid is mainly divided into exogenous uric acid and endogenous uric acid, the exogenous uric acid is mainly taken in by food, the endogenous uric acid is mainly generated by catalyzing xanthine and hypoxanthine by XOD, the excessive uric acid is generated when the XOD in a body is increased, and the hyperuricemia is caused by overhigh uric acid concentration so as to cause the gout. The common clinical methods for treating hyperuricemia include reducing uric acid generation, promoting excretion and the like, so that the reduction of XOD activity and the promotion of uric acid excretion are good targets for treating gout (extraction and purification of total flavonoids of caulis et folium Periplocae Forrestii and in-vitro anti-xanthine oxidase activity screening, journal of international pharmaceutical research, 7 months in 2019).

At present, the medicines for clinically treating gout mainly comprise allopurinol, cysteine, Interleukin (IL) -1 beta antibody, colchicine, non-steroidal anti-inflammatory drugs, glucocorticoid and the like. But the toxic and side effects are not negligible, so that the search for drugs which inhibit XOD activity and have high efficiency and low toxicity is necessary.

Cryptoporus volvatus is a dry fruiting body of Cryptoporus volvatus of the family Polyporaceae, is mainly distributed in China, Korea, Japan, Europe and North America, has slightly bitter taste and dry nature, has the effects of relieving cough, relieving asthma, detoxifying and the like, and is conveniently used for treating tracheitis and asthma from 15 th century in China. According to the reports of the literature, cryptoporus volvatus contains sesquiterpene, ergosterol, amino acid, polysaccharide and other bioactive components, and has pharmacological effects of resisting inflammation, oxidation, tumors, cytotoxicity and the like.

There is no disclosure of the research of cryptoporus volvatus fruiting body polysaccharide for inhibiting xanthine oxidase activity to treat gout.

Disclosure of Invention

The invention aims to overcome the defects of the prior art and provides cryptoporus volvatus sporocarp polysaccharide and application thereof in inhibiting xanthine oxidase activity to treat gout.

The purpose of the invention is realized by the following technical scheme:

a cryptoporus volvatus fruiting body polysaccharide is prepared by the following method: taking dried cryptoporus volvatus sporophore powder, heating and extracting with distilled water, filtering the extract, concentrating under reduced pressure, adding 3 times volume of anhydrous ethanol, standing overnight at 4 ℃, centrifuging, collecting precipitate, washing, redissolving with distilled water, deproteinizing by Sevag method, and freeze drying to obtain crude polysaccharide; taking the crude polysaccharide, redissolving the crude polysaccharide by using distilled water, loading the crude polysaccharide into a DEAE-Sepharose Fast Flow chromatographic column, eluting the crude polysaccharide by using distilled water and 1mol/LNaCl solution in sequence, collecting NaCl solution eluent, concentrating the eluent under reduced pressure, dialyzing the eluent, and freeze-drying the eluent to obtain the cryptoporus volvatus sporophore polysaccharide.

Further, the precipitate obtained by water extraction and alcohol precipitation is washed by 75% ethanol, absolute ethanol and acetone in sequence.

Further, when DEAE-Sepharose Fast Flow column chromatography was eluted, the elution volume of distilled water was 10 column volumes.

Further, when DEAE-Sepharose Fast Flow column was eluted, the elution volume of 1mol/LNaCl solution was 12 column volumes.

The application of the above cryptoporus volvatus fruiting body polysaccharide in inhibiting xanthine oxidase activity is provided.

The application of the cryptoporus volvatus fruiting body polysaccharide in preparing anti-gout medicines is provided.

The technical effects are as follows:

the invention discovers that the cryptoporus volvatus sporocarp polysaccharide has stronger inhibitory activity on xanthine oxidase. As known to those skilled in the art, hyperuricemia and gout are both caused by hyperuricemia in body fluid, uric acid is mainly divided into exogenous uric acid and endogenous uric acid, the exogenous uric acid is mainly taken in by food, the endogenous uric acid is mainly generated by catalyzing xanthine and hypoxanthine through XOD, hyperuricemia is generated when the XOD in a body is increased, and the hyperuricemia is caused by the excessive uric acid concentration, so that the gout is caused. Therefore, the cryptoporus volvatus fruiting body polysaccharide has a prospect of being developed into an anti-gout medicine.

Drawings

FIG. 1 is an SEM picture of polysaccharides from a fruiting body of cryptoporus volvatus.

Detailed Description

The following examples are presented to illustrate the essence of the present invention, but should not be construed as limiting the scope of the present invention.